At-Home Use of a Pregnancy-Specific Zone-MPC Closed-Loop System for Pregnancies Complicated by Type 1 Diabetes: A Single-Arm, Observational Multicenter Study

• Published in: Diabetes care Vol. 46; no. 7; pp. 1425 - 1431
• Main Authors: Levy, Carol J, Kudva, Yogish C, Ozaslan, Basak, Castorino, Kristin, O'Malley, Grenye, Kaur, Ravinder Jeet, Levister, Camilla M, Church, Mei Mei, Desjardins, Donna, McCrady-Spitzer, Shelly, Ogyaadu, Selassie, Trinidad, Mari Charisse, Reid, Corey, Rizvi, Shafaq, Deshpande, Sunil, Zaniletti, Isabella, Kremers, Walter K, Pinsker, Jordan E, Doyle, Francis J, Dassau, Eyal
• Format: Journal Article
• Language: English
• Published: United States American Diabetes Association 01.07.2023
• Subjects: Blood Glucose; Blood Glucose Self-Monitoring - methods; Closed loops; Cross-Over Studies; Customization; Diabetes; Diabetes mellitus; Diabetes mellitus (insulin dependent); Diabetes Mellitus, Type 1 - drug therapy; Feasibility studies; Feedback control; Female; Gestational age; Glucose; Glucose monitoring; Humans; Hybrid systems; Hypoglycemic Agents - therapeutic use; Infant; Insulin; Insulin - therapeutic use; Insulin Infusion Systems; Insulin, Regular, Human - therapeutic use; Original; Predictive control; Pregnancy; Pregnancy Outcome; Research design
• ISSN: 0149-5992; 1935-5548
• DOI: 10.2337/dc23-0173

There are no commercially available hybrid closed-loop insulin delivery systems customized to achieve pregnancy-specific glucose targets in the U.S. This study aimed to evaluate the feasibility and performance of at-home use of a zone model predictive controller-based closed-loop insulin delivery system customized for pregnancies complicated by type 1 diabetes (CLC-P). Pregnant women with type 1 diabetes using insulin pumps were enrolled in the second or early third trimester. After study sensor wear collecting run-in data on personal pump therapy and 2 days of supervised training, participants used CLC-P targeting 80-110 mg/dL during the day and 80-100 mg/dL overnight running on an unlocked smartphone at home. Meals and activities were unrestricted throughout the trial. The primary outcome was the continuous glucose monitoring percentage of time in the target range 63-140 mg/dL versus run-in. Ten participants (HbA1c 5.8 ± 0.6%) used the system from mean gestational age of 23.7 ± 3.5 weeks. Mean percentage time in range increased 14.1 percentage points, equivalent to 3.4 h per day, compared with run-in (run-in 64.5 ± 16.3% versus CLC-P 78.6 ± 9.2%; P = 0.002). During CLC-P use, there was significant decrease in both time over 140 mg/dL (P = 0.033) and the hypoglycemic ranges of less than 63 mg/dL and 54 mg/dL (P = 0.037 for both). Nine participants exceeded consensus goals of above 70% time in range during CLC-P use. The results show that the extended use of CLC-P at home until delivery is feasible. Larger, randomized studies are needed to further evaluate system efficacy and pregnancy outcomes.